Protein May Prevent Death of Neurons in Patients With Parkinson’s, Study Finds

Protein May Prevent Death of Neurons in Patients With Parkinson’s, Study Finds

Researchers have discovered that a protein called Nrf2 is capable of maintaining healthy levels of certain proteins linked to Parkinson’s disease, so as to protect neurons from cell death. The research could lead to new therapeutic targets for Parkinson’s and other neurodegenerative diseases.

The study, “Nrf2 mitigates LRRK2- and α-synuclein–induced neurodegeneration by modulating proteostasis,” was published in Proceedings of the National Academy of Sciences (PNAS).

Several neurodegenerative diseases, including Parkinson’s, Huntington’s disease, Alzheimer’s, and amyotrophic lateral sclerosis (ALS) share a common mechanism: the accumulation of incorrectly folded proteins (misfolded) in neurons, which eventually kill the nerve cells.

Researchers led by Dr. Steven Finkbeiner at the Gladstone Institutes investigated whether a protein called nuclear factor erythroid 2-related factor (Nrf2) could mitigate the deleterious effects induced by misfolded protein accumulation.

They tested Nrf2’s ability to prevent the damage associated with two proteins commonly affected by Parkinson’s disease — LRRK2 and alpha-synuclein. They found that activating Nrf2 induced cells-intrinsic “cleaning” mechanisms capable of removing the excessive proteins.

“Nrf2 coordinates a whole program of gene expression, but we didn’t know how important it was for regulating protein levels until now,” Dr. Gaia Skibinski, the study’s first author and a staff research scientist at Gladstone, said in a press release. “Overexpressing Nrf2 in cellular models of Parkinson’s disease resulted in a huge effect. In fact, it protects cells against the disease better than anything else we’ve found.”

Researchers used induced pluripotent stem cells to create neurons from rats or humans. They then manipulated those neurons to express Nrf2 and one of the proteins, either mutant LRRK2 or alpha-synuclein. Using a microscope, they tracked each neuron and measured over time the neuron’s protein levels and health.

Nrf2 exerts its “cleaning” by different processes, the researchers found: It promotes the formation of harmless mutant LRRK2 clumps inside cells or, quite the opposite, it induces alpha-synuclein degradation and clearance, decreasing the levels of the protein inside cells.

“I am very enthusiastic about this strategy for treating neurodegenerative diseases,” said Finkbeiner, the lead author. “We’ve tested Nrf2 in models of Huntington’s disease, Parkinson’s disease, and ALS, and it is the most protective thing we’ve ever found. Based on the magnitude and the breadth of the effect, we really want to understand Nrf2 and its role in protein regulation better.”

Researchers are trying to devise a strategy that could allow for therapeutic targeting of Nrf2 or its downstream effectors.

4 comments

  1. Frank Mundo says:

    My comment is “Its wonderful to announce these things and be ‘excited’ . . . but when will testing begin so that efficacy can be established ? These announcements may be great to fluff up people’s resumes, but they are simply “teasers” to people on the degeneration conveyor belt. Most of us will be pushing up daisies when a therapy is available. Look at Nilotinib (a case in point) – “announced in mid 2015 after initial positive tests . . . Michael J. Fox Foundation may start clinical tests “sometime in 2017”. Where is the URGENCY?

    • Tim Bossie says:

      We can completely understand what you are saying and how you feel. It is frustrating when these new things are found, but do not turn up any real significant treatment. Hopefully all of these steps forward will lead to something big soon so that people will get real help.

    • amanda vazquez says:

      You have nothing to lose and everything to gain by implementing this nutritional strategy now. It’s not about drugs my friend. Sometimes the answers are right there and we just aren’t aware. Amanda Vazquez

  2. Judy says:

    i tend to agree as i have been in several clinical trials myself over the last 8 years of my diagnosis. unfortunately, my gut gave way all of last year and i dramatically lost 90 lbs due to dysfunction or too much/too long of cd/ld. either way, my ans is bearing up under tough times. there is too much disagreement and not enough research it seems being done on the non-motor symptoms. now i have to be extremely cautious of any new trials. but i am still willing to try. non-motor are very dibilitating.

Leave a Comment

Your email address will not be published. Required fields are marked *